Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

Source The Motley Fool

Key Points

  • Both companies are working to move beyond their coronavirus vaccine windfalls.

  • These biotech players aim to make strides in cancer treatment.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

The coronavirus pandemic turned two little-known mRNA companies into household names. Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) brought their vaccines to market, collected billions of dollars in revenue, and then watched demand fade in recent years. Both stocks fell significantly from their highs, and both companies have spent the past few years trying to prove they're more than coronavirus vaccine makers.

This year, their paths have diverged. Moderna's stock has soared as investors rushed to bet on the company's promising personalized cancer vaccine program. BioNTech, meanwhile, saw its stock price slip and prepared to say goodbye to its founders.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

So, heading into 2027, which of these mRNA pioneers is the better buy?

Two investors look at something on a smartphone in a kitchen.

Image source: Getty Images.

Two companies, two different paths

First, a quick recap. Both companies have faced the same problem: the coronavirus vaccine was a windfall that couldn't last. Moderna's product sales peaked at more than $18 billion in 2022, and BioNTech's reached a high of about the same level in 2021. Each responded by cutting costs and shifting toward oncology. BioNTech has more than 25 phase 2 and phase 3 clinical trials ongoing in that treatment area. Moderna's personalized cancer vaccine candidate, intismeran autogene, is involved in four phase 3 trials and several earlier-stage trials.

BioNTech has real strengths. It has more than $17 billion in cash and investments, and its lead candidate, pumitamig, is a bispecific antibody it's developing with Bristol Myers Squibb. The company is evaluating pumitamig in seven global pivotal studies across several cancer types. Meanwhile, BioNTech recently had mixed results in a phase 3 trial of an antibody-drug conjugate with DualityBio. Though the candidate met its primary endpoint, its impact may be "limited," the companies said.

The coronavirus vaccine remains BioNTech's only commercialized product for the moment as we wait for the pipeline to potentially produce others. And the company will see its CEO, Uğur Şahin, and chief medical officer, Özlem Türeci, leave at year-end. A new CEO takes over by Feb. 1. That's a lot of change during a critical stretch.

Moderna's products and pipeline

Moderna, by contrast, has several commercialized products. Third-quarter revenue rose 29% to $1.3 billion, and net income was $162 million, a big swing from a loss a year earlier. Management raised its 2026 revenue growth outlook to a range of 15% to 25%, up from an earlier forecast of up to 10%. The biotech company now has five approved products, including a flu vaccine approved in the U.S. this year. A limited launch has already delivered more than 110,000 vaccinations, and Moderna is preparing a broader rollout for the 2027-2028 respiratory season.

The bigger prize is oncology, and in a phase 3 melanoma trial, intismeran plus Merck's Keytruda reduced the risk of recurrence or death by 42% compared with Keytruda alone. Intismeran is also in studies for lung, bladder, and kidney cancers, so melanoma could be just the first of several revenue streams.

Catalysts ahead in 2027

Next year offers several potential catalysts. Moderna and Merck said they'd be in contact with regulators about filing for intismeran approval, so investors should watch for submission news. Moderna will also provide formal 2027 financial guidance with its fourth-quarter report, and it's still awaiting FDA guidance on refiling its flu and COVID combination vaccine. Finally, in Europe, Moderna expects an opportunity to gain share as a competitor's COVID-19 vaccine contract expires.

Moderna isn't risk-free. The company still must gain regulatory approval for intismeran and prove the candidate's strength in several other clinical trials, and the stock's huge run raises expectations. Investors may see volatility around 2027 guidance.

BioNTech has the cash and a promising pipeline, and it may reward patient investors down the road. But its biggest opportunities are further out, and it's navigating a leadership overhaul along the way. Moderna offers a rarer combination: growing sales today, a cancer therapy that could reach the market soon, and a broadening vaccine lineup. That's why Moderna is my pick between the two, to buy and hold for the long term.

Should you buy stock in Moderna right now?

Before you buy stock in Moderna, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $322,605!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $927,581!*

Now, it’s worth noting Stock Advisor’s total average return is 790% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 20, 2026.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se, Bristol Myers Squibb, Merck, and Moderna. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 17, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
Author  Mitrade
Nov 17, Tue
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 18, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
Author  Mitrade
Nov 18, Wed
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 19, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
Author  Mitrade
Yesterday 03: 34
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
placeholder
Gold Price Forecast: XAU/USD regains ground below $3,700, outlook remains fragileGold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
Author  FXStreet
Yesterday 08: 46
Gold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 20, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 20, 2026. Read on for the details.
Author  Mitrade
6 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 20, 2026. Read on for the details.
goTop
quote